First Lab-in-a-Briefcase to Boost Global Early Diagnosis of Cancer
|
By LabMedica International staff writers Posted on 18 Nov 2015 |

Image: The 4 main components of the newly developed “lab-in-a-briefcase.” (1) Disposable multiple syringe aspirator (MSA) devices, each of which can perform 10 replicate ELISA tests on each of the 8 samples. (2) Customized microwell plates preloaded with reagents that interface with the MSA. (3) Portable USB-powered film scanner for colorimetric signal quantification. (4) Portable computer for real-time data analysis (Photo courtesy of Barbosa AI et al., 2015, and the journal Lab on a Chip.)
To help boost early cancer detection rates worldwide, scientists have developed an all-in-one portable mini-laboratory for point-of-care cancer screening, rapid detection, and monitoring. The prototype successfully tested for prostate cancer, and can operate at even at high temperatures often found in remote areas without air-conditioned clinics.
An estimated 70% of the world’s cancer deaths occur in Africa, Asia, and Central and South America. The lab-in-a-briefcase, believed to be a first-of-its-kind, was developed by a team from Loughborough University (Leicestershire, UK) and Capillary Film Technology, Ltd. (West Sussex,UK), led by Dr. Nuno Reis, lecturer in chemical engineering, Loughborough University.
One of the system’s remarkable features is the use whole blood without the need for sample preparation, which has been a challenging task for settings outside of a central laboratory. This also provides improved safety by minimizing the handling of blood samples from patients that may have infectious diseases.
The compact system, a complete miniaturized ELISA platform, comprises of 4 main components: a manually driven multi-syringe aspirator capable of performing up to 80 simultaneous tests from whole blood samples; microwell ELISA plates pre-loaded with assay reagents; a portable USB-powered film scanner to image test-strips; and a portable computer for real-time data analysis.
The easy-to-use, semi-automated system requires only one operator with minimal training to conduct the test within 15 minutes – with no need for additional equipment or instruments.
A new affordable, disposable microfluidic test-strip—comprising of tiny capillary tubes about the width of a human hair—is used specifically for quick measurement of different cancer biomarkers in a whole blood sample. This technology, which operates like a pregnancy test, has already been used successfully in a separate study led by Dr. Reis that detected prostate cancer with the help of a smartphone camera. The new, lab-in-a-briefcase study also focused on detecting prostate cancer (by testing for the PSA [prostate-specific antigen] biomarker); however the microfluidic test-strip is versatile enough to measure several cancer biomarkers simultaneously from a single sample.
“Our lab-in-a-briefcase is both inexpensive and simple to use; it means that high-precision diagnostic kits, complete with clinical laboratory equipment, can be made accessible to remote populations, and this is what makes it a truly life-changing concept for the screening and monitoring of different types of cancer,” said
Dr. Reis, “This portable lab can really make a difference, boosting levels of cancer detection in developing countries where ordinarily people would not have such easy access to early diagnostics. I envisage that our lab-in-a-briefcase could also be developed further in the future to allow for rapid testing of infectious diseases and allergens.”
The study, by Barbosa AI et al, was published in June, 2015, in the journal Lab on a Chip.
Related Links:
Loughborough University
Capillary Film Technology
An estimated 70% of the world’s cancer deaths occur in Africa, Asia, and Central and South America. The lab-in-a-briefcase, believed to be a first-of-its-kind, was developed by a team from Loughborough University (Leicestershire, UK) and Capillary Film Technology, Ltd. (West Sussex,UK), led by Dr. Nuno Reis, lecturer in chemical engineering, Loughborough University.
One of the system’s remarkable features is the use whole blood without the need for sample preparation, which has been a challenging task for settings outside of a central laboratory. This also provides improved safety by minimizing the handling of blood samples from patients that may have infectious diseases.
The compact system, a complete miniaturized ELISA platform, comprises of 4 main components: a manually driven multi-syringe aspirator capable of performing up to 80 simultaneous tests from whole blood samples; microwell ELISA plates pre-loaded with assay reagents; a portable USB-powered film scanner to image test-strips; and a portable computer for real-time data analysis.
The easy-to-use, semi-automated system requires only one operator with minimal training to conduct the test within 15 minutes – with no need for additional equipment or instruments.
A new affordable, disposable microfluidic test-strip—comprising of tiny capillary tubes about the width of a human hair—is used specifically for quick measurement of different cancer biomarkers in a whole blood sample. This technology, which operates like a pregnancy test, has already been used successfully in a separate study led by Dr. Reis that detected prostate cancer with the help of a smartphone camera. The new, lab-in-a-briefcase study also focused on detecting prostate cancer (by testing for the PSA [prostate-specific antigen] biomarker); however the microfluidic test-strip is versatile enough to measure several cancer biomarkers simultaneously from a single sample.
“Our lab-in-a-briefcase is both inexpensive and simple to use; it means that high-precision diagnostic kits, complete with clinical laboratory equipment, can be made accessible to remote populations, and this is what makes it a truly life-changing concept for the screening and monitoring of different types of cancer,” said
Dr. Reis, “This portable lab can really make a difference, boosting levels of cancer detection in developing countries where ordinarily people would not have such easy access to early diagnostics. I envisage that our lab-in-a-briefcase could also be developed further in the future to allow for rapid testing of infectious diseases and allergens.”
The study, by Barbosa AI et al, was published in June, 2015, in the journal Lab on a Chip.
Related Links:
Loughborough University
Capillary Film Technology
Latest Technology News
- AI Model Outperforms Clinicians in Rare Disease Detection
- AI-Driven Diagnostic Demonstrates High Accuracy in Detecting Periprosthetic Joint Infection
- Blood Test “Clocks” Predict Start of Alzheimer’s Symptoms
- AI-Powered Biomarker Predicts Liver Cancer Risk
- Robotic Technology Unveiled for Automated Diagnostic Blood Draws
- ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
- Aptamer Biosensor Technology to Transform Virus Detection
- AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
- AI-Generated Sensors Open New Paths for Early Cancer Detection
Channels
Clinical Chemistry
view channel
Blood Test Tracks Transplant Health Using Donor DNA
Organ transplantation offers life-saving treatment for patients with end-stage disease, but complications such as rejection remain a constant risk. Monitoring transplanted organs typically relies on invasive... Read more
AI Sensor Detects Neurological Disorders Using Single Saliva Drop
Neurological disorders such as Parkinson’s disease and Alzheimer’s disease often develop gradually and present subtle symptoms in their early stages. Because early signs are frequently vague or atypical,... Read moreMolecular Diagnostics
view channel
DNA Aptamers Offer New Tool for Easy Alzheimer's Blood Test
Alzheimer’s disease is the most common cause of dementia and is marked by progressive loss of nerve cells that begins many years before symptoms become noticeable. Detecting early signs of neurodegeneration... Read more
Jumping "DNA Parasites” Linked to Early Tumor Development
Cancer genomes accumulate complex structural variants that can be difficult to resolve with standard short-read sequencing, obscuring clinically relevant drivers of disease. Transposable elements, particularly... Read more
AI-Based Liquid Biopsy Detects Liver Fibrosis, Cirrhosis and Chronic Disease Signals
Liver fibrosis and cirrhosis often develop silently for years before symptoms appear, making early diagnosis difficult. Detecting these conditions earlier could allow treatment before irreversible damage... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response
Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more
Immune Signature Identified in Treatment-Resistant Myasthenia Gravis
Myasthenia gravis is a rare autoimmune disorder in which immune attack at the neuromuscular junction causes fluctuating weakness that can impair vision, movement, speech, swallowing, and breathing.... Read more
New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer
Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read moreBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read moreMicrobiology
view channel
Study Highlights Accuracy Gaps in Consumer Gut Microbiome Kits
Direct-to-consumer gut microbiome kits promise personalized insights by profiling fecal bacteria and generating health readouts, but their analytical accuracy remains uncertain. A new study shows that... Read more
WHO Recommends Near POC Tests, Tongue Swabs and Sputum Pooling for TB Diagnosis
Tuberculosis (TB) remains one of the world’s leading infectious disease killers, yet millions of cases go undiagnosed or are detected too late. Barriers such as reliance on sputum samples, limited laboratory... Read morePathology
view channel
Novel mcPCR Technology to Transform Testing of Clinical Samples
DNA methylation is an important biological marker used in the diagnosis and monitoring of many diseases, including cancer. These chemical modifications to DNA influence gene activity and can reveal early... Read more
Sex Differences in Alzheimer’s Biomarkers Linked to Faster Cognitive Decline
Sex differences in Alzheimer’s disease present ongoing diagnostic challenges, with women often experiencing a disproportionate disease burden even when preclinical amyloid-beta levels are similar to men.... Read moreIndustry
view channel
Agilent Technologies Acquires Pathology Diagnostics Company Biocare Medical
Agilent Technologies (Santa Clara, CA, USA) has entered into a definitive agreement to acquire Biocare Medical (Pacheco, CA, USA), expanding its pathology portfolio through the addition of highly complementary... Read more
Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss
Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio
QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more








